Gc Biopharma
Gc Biopharma, officially known as Green Cross Biopharma, is a leading biopharmaceutical company headquartered in South Korea (KR). Established in 1967, the company has made significant strides in the biopharmaceutical industry, focusing on the development and production of innovative therapies, particularly in the fields of immunology and infectious diseases. With a strong presence in Asia and expanding operations globally, Gc Biopharma is renowned for its core products, including plasma-derived therapies and vaccines. These offerings are distinguished by their high quality and efficacy, positioning the company as a trusted provider in the healthcare sector. Notable achievements include its commitment to research and development, which has propelled Gc Biopharma to a prominent market position, making it a key player in the biopharmaceutical landscape.
DitchCarbon Score
How does Gc Biopharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Gc Biopharma's score of 10 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Gc Biopharma's reported carbon emissions
In 2023, Gc Biopharma reported total carbon emissions of approximately 64,804,000 kg CO2e, with Scope 1 emissions at about 10,804,000 kg CO2e and Scope 2 emissions at around 54,001,000 kg CO2e. This marked a slight decrease from 2022, where total emissions were approximately 66,854,000 kg CO2e. Over the years, Gc Biopharma's emissions have fluctuated, with total emissions reaching about 68,166,000 kg CO2e in 2021 and 64,319,000 kg CO2e in 2020. The company has disclosed emissions data for Scope 1 and Scope 2, but there are no specific reduction targets or initiatives outlined in their current commitments. Gc Biopharma's climate strategy appears to be in the early stages, as there are no documented reduction targets or climate pledges available. The company is situated in a sector that increasingly prioritises sustainability, and as such, it may benefit from establishing clear reduction goals to align with industry standards and expectations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 9,651,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 42,240,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Gc Biopharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
